Azilsartan

EDARBI

What it isAngiotensin AT1 receptor antagonist; hypertension.

Why this oneIt generally produces greater blood-pressure reduction than older ARBs, but has less long-term outcomes experience.

What limits itHyperkalemia and a hemodynamic creatinine rise require monitoring; contraindicated in pregnancy.

FDA-approved for

BOXED WARNING Fetal toxicity — discontinue as soon as pregnancy is detected; RAAS-acting drugs can injure and kill the developing fetus.

FDA dosing	Population	Start	Target	Max
Hypertension	Adult	80 mg QD (40 mg if on high-dose diuretics)	80 mg QD	80 mg QD

Renal No adjustment needed (mild-to-severe impairment or ESRD)

Hepatic No adjustment for mild-moderate impairment; not studied in severe

Take once daily with or without food
Dispense/store in original container to protect from light and moisture; do not repackage
May be given with other antihypertensives

Fetal toxicity — discontinue when pregnancy detected (boxed)
Symptomatic hypotension in volume-/salt-depleted patients — correct depletion or start at 40 mg
Worsening renal function in RAAS-dependent patients (renal artery stenosis, severe CHF, volume depletion)

Pregnancy Can cause fetal harm (oligohydramnios, fetal/neonatal renal failure, death); discontinue when pregnancy detected

Lactation Breastfeeding not recommended

⚠ BOXED WARNING

Cost, est. cash$300–$2,500/month

Generic entry2022

Therapeutic safety burden2 / 4

Overdose danger2 / 4

Weight-gain liability0 / 4

Sedation liability0 / 4

QT / Torsades0 / 4

Direct muscarinic antagonism0 / 4

Embryofetal risk4 / 4

Legacy pregnancy categoryD

Defining liabilityHyperkalemia, kidney injury, fetal toxicity and increased lithium exposure.

Box: minimal PK interactions